



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that by virtue of an assignment registered under the Patents Act 1977, the application is now proceeding in the name as substituted.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

12 DEC 2000

GB0004232.5


By virtue of a direction given under Section of the Patents Act 1977, the application is proceeding in the name of

ASTRAZENECA AB,  
Incorporated in Sweden,  
S-151 85 Sodertalje,  
Sweden

[ADP No. 07822448003]

Patents Form 1/77

Patents Act 1977



24FEB00 1515675+1 0004232.5  
P01/7700 0.00-0004232.5

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

24 FEB 2000

1. Your reference

LDSG/PHM00-004/GB/P

2. Patent application number

(The Patent Office will fill in this part)

0004232.5

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

AstraZeneca UK Limited  
15 Stanhope Gate  
London, W1X 6LJ  
United Kingdom.

SECTION 3(1) ACT APPLICATION FILED 4/7/2000

Patents ADP number (*if you know it*)

6254007002

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

DIAGNOSTIC METHOD

5. Name of your agent (*if you have one*)

BILL, Kevin

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

AstraZeneca  
Global Intellectual Property, Patents.  
Mereside, Alderley Park,  
Macclesfield, Cheshire. SK10 4TG.  
United Kingdom.

Patents ADP number (*if you know it*)

4469847002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)

Date of filing  
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or

## Patents Form 1/77

Do not count copies of the same document

Continuation sheets of this form

31

Description

Claim(s)

Abstract

Drawing(s)

10. If you are also filing any of the following,  
state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right  
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination  
and search (*Patents Form 9/77*)

Request for substantive examination  
(*Patents Form 10/77*)

Any other documents  
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*Lynda M. Slack*, Date 23 Feb 2000  
AstraZeneca UK Limited, Authorised Signatory.

12. Name and daytime telephone number of  
person to contact in the United Kingdom

Mrs Lynda Slack - tel. 01625 516173

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*

### DIAGNOSTIC METHOD

This invention relates to novel sequence and polymorphisms in the human *flt-1* gene. The invention also relates to methods and materials for analysing allelic variation in the *flt-1* gene and to the use of *flt-1* polymorphism in the diagnosis and treatment of angiogenic diseases and cancer. Diseases associated with pathological angiogenesis include diabetic retinopathies, psoriasis, rheumatoid arthritis and endometriosis.

*Flt-1* is one of the two receptors for vascular endothelial growth factor (VEGFR-1). The other being KDR (VEGFR-2). The *flt-1* protein consists of an external domain containing seven immunoglobulin like domains, a transmembrane region and a cytoplasmic region containing a tyrosine kinase domain. In contrast to other members of the receptor tyrosine kinase family, the kinase domain of *flt-1* is in two segments with an intervening sequence of ~70 amino acids. The biology of the VEGF receptors has been reviewed (Neufeld et al., (1999) FASEB Journal. 13:11-22; Zachary (1998) Experimental Nephrology. 6:480-487) and the tyrosine phosphorylation sites have been identified (Ito et al., (1998) J. Biol. Chem. 273:23410-23418).

It is thought that *flt-1* may be important in regulating the tissue architecture in developing vasculature while the second VEGF receptor (KDR, VEGFR-2) mediates the mitogenic and angiogenic effects of VEGF in endothelial cells. Evidence to support this theory has come from knockout studies in mice (Fong et al., (1995) Nature. 376:66-70).

VEGF and its receptors are over expressed in many tumour types and blocking of VEGF function inhibits angiogenesis and suppresses growth of tumours while over expression of VEGF enhances angiogenesis and tumour growth (Skobe et al., (1997) Nature Medicine 3:1222-1227). Several studies have now shown that modulation of *flt-1* activity can lead to anti-tumour activity. A small molecule inhibitor, SU5416, was originally developed against KDR but has been shown to be active against *flt-1*, the authors propose that inhibition of *flt-1* may lead to interference with the formation of endothelial-matrix interactions (Fong et al., (1999) Cancer Research. 59:99-106).

Alternative strategies to modulate *flt-1* activity have included the use of ribozymes (Parry et al., (1999) Nucleic Acids Research. 27:2569-2577), the synthesis of aptamers to inhibit binding of VEGF to its receptor (Ruckman et al., (1998) J Biol Chem. 273:20556-20567) and the *in vivo* transfer of the *flt-1* external domain (Kong et al., (1998) Human Gene

Therapy. 9:823-833). Chimeric toxins containing VEGF fused to the diphtheria toxin have been used to target endothelial cells (Arora et al., (1999) Cancer Research. 59:183-188).

The flt-1 cDNA (EMBL Accession Number X51602, 7680 bp) encodes a mature protein of 1338 amino acids. The structure of the murine flt-1 gene has been determined  
5 (Kondo *et al.*, (1998) Gene 208:297-305) and has been used to predict the intron/exon boundaries within the human gene. The promoter region of the human gene has been characterised (Ikeda *et al.*, (1996) Growth Factors. 13:151-162; Morishita *et al.*, (1995) J Biol Chem 270:27948-27953; EMBL Accession Number D64016, 1745 bp). The flt-1 gene, which is organised into thirty exons, has been localised to chromosome 13q12 (Rosnet et al. (1993)  
10 Oncogene 8:73-179).

Unless otherwise indicated or apparent from the context, all exon positions herein relate to the positions indicated in EMBL Accession X51602, all promoter positions relate to the positions indicated in EMBL Accession No. 64016, and all intron sequences relate to one or other of SEQ ID Nos 1 - 5 disclosed herein.

15 SEQ ID No. 1 (1073 bp) represents exon 17 (positions 483 - 615 corresponding to positions 2605-2737 in EMBL Accession No. X51602) and adjacent intron sequences (positions 1-482 and 616-1073).

SEQ ID No. 2 (1480 bp) represents exon 21 (positions 438 - 594 corresponding to positions 3046-3202 in EMBL Accession No. X51602), exon 22 (positions 1025-1122  
20 corresponding to positions 3203-3300 in EMBL Accession No. X51602) and intron sequences adjacent these exons (positions 1-437, 595-1024 and 1123-1480).

SEQ ID No. 3 (726 bp) represents exon 24 (positions 267-278 corresponding to positions 3424-3535 in EMBL Accession No. X51602) and adjacent intron sequences (positions 1-266 and 279-726).

25 SEQ ID No. 4 (1352 bp) represents exon 26 (positions 285-390 corresponding to positions 3636-3741 in EMBL Accession No. X51602), exon 27 (positions 652-794 corresponding to positions 3742-3884 in EMBL Accession No. X51602) and intron sequences adjacent these exons (positions 1-284, 391-651 and 795-1352).

SEQ ID No. 5 (1256 bp) represents exon 28 (positions 580-664 corresponding to  
30 positions 3885-3969 in EMBL Accession No. X51602) and adjacent intron sequences (positions 1-579 and 665-1256).

The novel intron sequence, or parts thereof, can be used, *inter alia*, as hybridisation probes to identify clones harbouring the *flt-1* gene, for use in genetic linkage studies or for design and use as amplification primers suitable, for example, to amplify some or all of the *flt-1* gene using an amplification reaction such as the PCR.

5 Polymorphism refers to the occurrence of two or more genetically determined alternative alleles or sequences within a population. A polymorphic marker is the site at which divergence occurs. Preferably markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably at least 10%, 15%, 20%, 30% or more of a selected population.

10 Single nucleotide polymorphisms (SNP) are generally, as the name implies, single nucleotide or point variations that exist in the nucleic acid sequence of some members of a species. Such polymorphism variation within the species are generally regarded to be the result of spontaneous mutation throughout evolution. The mutated and normal sequences co-exist within the species' population sometimes in a stable or quasi-stable equilibrium. At  
15 other times the mutation may confer some selective advantage to the species and with time may be incorporated into the genomes of all members of the species.

Some SNPs occur in the protein coding sequences, in which case, one of the polymorphic protein forms may possess a different amino acid which may give rise to the expression of a variant protein and, potentially, a genetic disease. Recently, it has been  
20 reported that even polymorphisms that do not result in an amino acid change can cause different structural folds of mRNA with potentially different biological functions (Shen *et al.*, (1999) *Proc Natl Acad Sci USA* 96:7871-7876). Changes that occur outside of the coding region, i.e. intron sequences, promoter regions etc may affect the transcription and/or message stability of the sequences and thus affect the level of the protein (receptor) in cells.

25 The use of knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents is often termed "pharmacogenetics". Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background  
30 details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), *Clinical Chemistry*, 43:254; Marshall (1997), *Nature Biotechnology*, 15:1249; International

Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.*, (1998), Nature Biotechnology, 16:33.

A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as  $2^n$  haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

Clinical trials have shown that patient response to drugs is heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example, "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

The present invention is based on the discovery of nine novel single nucleotide polymorphisms as well as novel intronic sequence of the flt-1 gene. Relative to EMBL Accession No. X51602 the three novel coding sequence polymorphisms are located at nucleotide position: 1953, 3453 and 3888. Relative to EMBL Accession No. D64016 the four novel promoter sequence polymorphisms are located at nucleotide position: 519, 786, 1422.



and 1429. Relative to SEQ ID No.3, the intron 24 polymorphism is located at position 454. Relative to SEQ ID No.5, the intron 28 polymorphism is located at position 696.

For the avoidance of doubt the location of each of the polymorphisms (emboldened: published allele (if published) illustrated first) and sequence immediately flanking each polymorphism site is as follows:

Numbering according to EMBL Accession X51602

a) Position 1953 (codon 568 polymorphism)

GGAAAAAATGCCGAC**G**/AGAAGGAGAGGACCTG (SEQ ID No. 6)  
10 1938 1968

b) Position 3453 (codon 1068 polymorphism)

GAAATGGATGGCTCCC/TGAATCTATCTTTGAC (SEQ ID No. 7)  
3438 3468

15

c) Position 3888 (codon 1213 polymorphism)

TGATGATGTCAGATAT/CGTAAATGCTTTCAAG (SEQ ID No. 8)  
3873 3903

20 Numbering according to EMBL Accession D64016

d) Position 519 (promoter polymorphism)

AAAAAGACACGGACAC/TGCTCCCCTGGGACCT (SEQ ID No. 9)  
504 534

25

e) Position 786 (promoter polymorphism)

GATCGGACTTTCCGCC/TCCTAGGGCCAGGCGG (SEQ ID No.10)  
771 801

30 f) Position 1422 (promoter polymorphism)

GACGGACTCTGGCGGC/TCGGGTCTTTGGCCGC (SEQ ID No. 11)  
1407 1437

g) Position 1429 (promoter polymorphism)

TCTGGCGGCCCGGGTCG/TTTGGCCGCGGGGAGC (SEQ ID No. 12)

1414

1434

5

Numbering according to Seq ID 3 (intron 24)

h) Intron 24 position 454

GAATGTCCTTTGGTTG/AGACAGCCTTTAGATT (SEQ ID No. 13)

10 439

469

Numbering according to Seq ID No 5 (intron 28)

i) Intron 28 position 696

15 AGGTACCTAGTGCAC/CCCGATAGACCCCTTC (SEQ ID No. 14)

681

711

According to one aspect of the present invention there is provided a method for the diagnosis of one or more single nucleotide polymorphism(s) in *flt-1* gene in a human, which  
20 method comprises determining the sequence of the nucleic acid of the human at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), and determining the status of the human by reference to polymorphism in the *flt-1* gene.

25 The term human includes both a human having or suspected of having a *flt-1* ligand-mediated disease and an asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

As defined herein, the *flt-1* gene includes exon coding sequence, intron sequences  
30 intervening the exon sequences and, 3' and 5' untranslated region (3' UTR and 5' UTR) sequences, including the promoter element of the *flt-1* gene.

In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 1953 (according to the position in EMBL accession number X51602) is the presence of G and/or A.

5 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 3453 (according to the position in EMBL accession number X51602) is the presence of C and/or T.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 3888 (according to the position in EMBL accession number X51602) is the presence of T and/or C.

10 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 519 (according to the position in EMBL accession number D64016) is the presence of C and/or T.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 786 (according to the position in EMBL accession number D64016) is the presence of C and/or T.

15 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 1422 (according to the position in EMBL accession number D64016) is the presence of C and/or T.

In another embodiment of the invention preferably the method for diagnosis described 20 herein is one in which the single nucleotide polymorphism at position 1429 (according to the position in EMBL accession number D64016) is the presence of G and/or T.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 454 (according to the position in SEQ ID No. 3) is the presence of G and/or A.

25 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 696 (according to the position in SEQ ID No. 5) is the presence of T and/or C.

The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system (ARMST<sup>TM</sup>-allele specific 30 amplification), allele specific hybridisation (ASH), oligonucleotide ligation assay (OLA) and restriction fragment length polymorphism (RFLP).

In another aspect of the invention there is provided a method of analysing a nucleic acid, comprising: obtaining a nucleic acid from an individual; and determining the base occupying any one of the following polymorphic sites: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5).

In another aspect of the invention we provide a method for the diagnosis of flt-1 ligand-mediated disease, which method comprises:

- i) obtaining sample nucleic acid from an individual;
- 10 ii) detecting the presence or absence of a variant nucleotide at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the flt-1 gene; and
- iii) determining the status of the individual by reference to polymorphism in the flt-1 gene.

15 Allelic variation at position 1953 (according to EMBL sequence X51602) consists of a single base substitution from G (the published base), for example to A. Allelic variation at position 3453 (according to EMBL sequence X51602) consists of a single base substitution from C (the published base), for example to T. Allelic variation at position 72 (according to EMBL sequence X51602) consists of a single base substitution from T (the published base), for example to C. Allelic variation at position 519 (according to EMBL sequence D64016), consists of a single base substitution from C (the published base), for example to T. Allelic variation at position 786 (according to EMBL sequence D64016), consists of a single base substitution from C (the published base), for example to T. Allelic variation at position 1422 (according to EMBL sequence D64016), consists of a single base substitution from C (the published base), for example to T. Allelic variation at position 1429 (according to EMBL sequence D64016), consists of a single base substitution from G (the published base), for example to T. Allelic variation at position 454 (according to SEQ ID No. 3) consists of a single base substitution from C to G, for example. Allelic variation at position 454 (according to SEQ ID No. 5) consists of a single base substitution from T to C, for example.

30 The invention resides in the identification of the existence of different alleles at particular loci. The status of the individual may be determined by reference to allelic variation at one or more of the above loci.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, urine or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before use in the analysis of sequence variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of one or more of the polymorphisms identified herein. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2<sup>nd</sup> Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

#### Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMST™	Amplification refractory mutation system
ASH	Allele specific hybridisation
b-DNA	Branched DNA
CMC	Chemical mismatch cleavage
bp	base pair
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay

NASBA	Nucleic acid sequence based amplification
flt-1	VEGF receptor-1
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SERRS	Surface enhanced raman resonance spectroscopy
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis

**Table 1 - Mutation Detection Techniques**

**General:** DNA sequencing, Sequencing by hybridisation

**Scanning:** PTT\*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic  
5 mismatch cleavage

\* Note: not useful for detection of promoter polymorphisms.

**Hybridisation Based**

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide  
arrays (DNA Chips)

10 Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La  
Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, **14**, 303; WO  
95/13399 (Public Health Inst., New York), ASH

**Extension Based:** ARMST™-allele specific amplification (as described in European patent  
No. EP-B-332435 and US patent No. 5,595,890), ALEX™ - European Patent No. EP 332435  
15 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, **17**, 2347.

**Incorporation Based:** Mini-sequencing, APEX

**Restriction Enzyme Based:** RFLP, Restriction site generating PCR

**Ligation Based:** OLA- Nickerson *et al.* (1990) P.N.A.S. **87**:8923-8927.

**Other:** Invader assay

**Table 2 - Signal Generation or Detection Systems**

**Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

- 5 **Other:** Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry, SERRS - WO 97/05280 (University of Strathclyde).

**Table 3 - Further Amplification Methods**

- 10 SSR, NASBA, LCR, SDA, b-DNA

Preferred mutation detection techniques include ARMST<sup>TM</sup>-allele specific amplification, ALEX<sup>TM</sup>, COPS, Taqman, Molecular Beacons, RFLP, OLA, restriction site based PCR and FRET techniques.

- Particularly preferred methods include ARMST<sup>TM</sup>-allele specific amplification, OLA  
15 and RFLP based methods. The allele specific amplification technique known in the art as ARMST<sup>TM</sup> is an especially preferred method.

- ARMST<sup>TM</sup>-allele specific amplification (described in European patent No. EP-B-332435, US patent No. 5,595,890 and Newton et al. (Nucleic Acids Research, Vol. 17, p.2503; 1989)), relies on the complementarity of the 3' terminal nucleotide of the primer and  
20 its template. The 3' terminal nucleotide of the primer being either complementary or non-complementary to the specific mutation, allele or polymorphism to be detected. There is a selective advantage for primer extension from the primer whose 3' terminal nucleotide complements the base mutation, allele or polymorphism. Those primers which have a 3' terminal mismatch with the template sequence severely inhibit or prevent enzymatic primer  
25 extension. Polymerase chain reaction or unidirectional primer extension reactions therefore result in product amplification when the 3' terminal nucleotide of the primer complements that of the template, but not, or at least not efficiently, when the 3' terminal nucleotide does not complement that of the template.

- Therapeutic opportunities for VEGF receptor antagonists exist for angiogenic and  
30 cancer diseases. An example of a known inhibitor of flt-1 is SU5416 (*supra*).

In a further aspect, the diagnostic methods of the invention are used to assess the efficacy of therapeutic compounds in the treatment of angiogenic diseases, such as diabetic retinopathies, psoriasis, rheumatoid arthritis and endometriosis, and cancer.

The polymorphisms identified in the present invention that occur in intron regions or  
5 in the promoter region are not expected to alter the amino acid sequence of the flt-1 receptor, but may affect the transcription and/or message stability of the sequences and thus affect the level of the receptors in cells.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

10 Individuals who carry particular allelic variants of the flt-1 gene, especially those within the promoter element, may therefore exhibit differences in receptor levels under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences in receptor level arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. Flt-1 polymorphism may  
15 therefore have the greatest effect on the efficacy of drugs designed to modulate the activity of the flt-1. However, the polymorphisms may also affect the response to agents acting on other biochemical pathways regulated by a flt-1 ligand. The diagnostic methods of the invention may therefore be useful both to predict the clinical response to such agents and to determine therapeutic dose.

20 In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by an flt-1 ligand.

Flt-1 gene polymorphism may be particularly relevant in the development of diseases modulated by an flt-1 ligand. The present invention may be used to recognise individuals who are particularly at risk from developing these conditions.

25 In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the flt-1 gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated  
30 in the disease process whilst minimising effects on other variants.

In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites



recognised by restriction enzymes. For example the polymorphism at position 3888 that alters the third base of codon 1213 can be detected by digestion with the restriction enzyme Sna IB, as polymorphism at this position creates a Sna IB recognition sequence (TACGTA).

Engineered sites include those wherein the primer sequences employed to amplify the  
5 target sequence participates along with the nucleotide polymorphism to create a restriction site. For example, the polymorphism at position 519 can be detected by diagnostic engineered RFLP digestion with the restriction enzyme Sph I, since modification of position 516 creates a potential Sph I I recognition sequence (GCATGC). Polymorphism at position 519 will modify the recognition sequence (GCAC/TGC).

10 The person of ordinary skill will be able to design and implement diagnostic procedures based on the detection of restriction fragment length polymorphism due to the loss or gain of one or more of the sites.

According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymorphisms:

- 15 the nucleic acid disclosed in EMBL Accession Number X51602 with A at position 1953 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number X51602 with T at position 3453 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number X51602 with C at position  
20 3888 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 519 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 786 according to the nucleotide positioning therein;  
25 the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 1422 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 1429 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in SEQ ID No. 3 with G at position 454 according to the  
30 nucleotide positioning therein;  
the nucleic acid sequence disclosed in SEQ ID No. 3 with A at position 454 according to the nucleotide positioning therein;

the nucleic acid sequence disclosed in SEQ ID No. 5 with T at position 696 according to the nucleotide positioning therein;

the nucleic acid sequence disclosed in SEQ ID No. 5 with C at position 696 according to the nucleotide positioning therein;

- 5 or a complementary strand thereof or a fragment thereof of at least 17 bases comprising at least one of the polymorphisms.

According to another aspect of the present invention there is provided an isolated nucleic acid comprising at least 17 consecutive bases of flt-1 gene said nucleic acid comprising one or more of the following polymorphic alleles: A at position 1953 (according  
10 to X51602), T at position 3453 (according to X51602), C at position 3888 (according to X51602), T at position 519 (according to D64016), T at position 786 (according to D64016), T at position 1422 (according to D64016), T at position 1429 (according to D64016), A at position 454 (according to SEQ ID No. 3) and C at position 696 (according to SEQ ID No. 5), or a complementary strand thereof.

- 15 Fragments are at least 17 bases more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides nucleotide primers which detect the flt-1 gene polymorphisms of the invention. Such primers can be of any length, for example between 8 and 100 nucleotides in length, but will preferably be between 12 and 50 nucleotides in length.  
20 more preferable between 17 and 30 nucleotides in length.

According to another aspect of the present there is provided an allele specific primer capable of detecting an flt-1 gene polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to  
25 SEQ ID No. 3) and 696 (according to SEQ ID No. 5).

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as PCR, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™ allele specific amplification assays. The allele specific primer is preferably 17- 50  
30 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer. Often the nucleotide at the -2 and/or -3 position (relative to the 3' terminus) is mismatched in order to optimise differential primer binding and preferential extension from the correct allele discriminatory primer only

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1<sup>st</sup> Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a *flt-1* gene polymorphism of the invention.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting an *flt-1* gene polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the *flt-1* gene.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. Suitable oligonucleotide probes might be those consisting of or comprising the sequences depicted in SEQ ID Nos. 6 - 14 possessing one or other of the central allelic base differences (emboldened), or sequences complementary thereto. The

probes or primers of the invention may carry one or more labels to facilitate detection, such as in Molecular Beacons.

According to another aspect of the present invention there is provided a diagnostic kit comprising one or more allele-specific primers of the invention and/or one or more allele-specific oligonucleotide probe of the invention.

The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase. Such kits may also comprise companion primers and/or control primers or probes. A companion primer is one that is part of the pair of primers used to perform PCR. Such primer usually complements the template strand precisely.

In another aspect of the invention, the single nucleotide polymorphisms of this invention may be used as genetic markers for this region in linkage studies. This particularly applies to the polymorphisms at positions 3453, 3888 (both according to the position in EMBL Accession No. X51602), position 1429 (according to the position in EMBL accession number D64016), position 454 (according to the position in SEQ ID No. 3) and position 696 (according to the position in SEQ ID No. 5) because of their relatively high frequency. Those polymorphisms that occur relatively infrequently are useful as markers of low frequency haplotypes.

According to another aspect of the present invention there is provided a method of treating a human in need of treatment with an flt-1 ligand antagonist drug in which the method comprises:

- i) diagnosis of a single nucleotide polymorphism in flt-1 gene in the human, which diagnosis comprises determining the sequence of the nucleic acid at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), and determining the status of the human by reference to polymorphism in the flt-1 gene; and
- ii) administering an effective amount of an flt-1 ligand antagonist drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which flt-1 ligand antagonist drug or drugs to administer and/or in deciding on the effective amount of the drug or drugs.

According to another aspect of the present invention there is provided use of an flt-1  
5 ligand antagonist drug in the preparation of a medicament for treating a VEGF-mediated disease in a human diagnosed as having a single nucleotide polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the flt-1  
10 gene.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising an flt-1 ligand antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position  
15 in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the flt-1 gene.

According to another aspect of the invention there is provided an isolated nucleic acid sequence comprising the sequence selected from the group consisting of:

- 20 (i) the nucleotide sequence from positions 1-482 of SEQ ID No. 1;
- (ii) the nucleotide sequence from positions 616-1073 of SEQ ID No. 1;
- (iii) the nucleotide sequence from positions 1-437 of SEQ ID No. 2;
- (iv) the nucleotide sequence from positions 595-1024 of SEQ ID No. 2;
- (v) the nucleotide sequence from positions 1123-1480 of SEQ ID No. 2;
- 25 (vi) the nucleotide sequence from positions 1-266 of SEQ ID No. 3;
- (vii) the nucleotide sequence from positions 279-726 of SEQ ID No. 3;
- (viii) the nucleotide sequence from positions 1-284 of SEQ ID No. 4;
- (ix) the nucleotide sequence from positions 391-651 of SEQ ID No. 4;
- (x) the nucleotide sequence from positions 795-1352 of SEQ ID No. 4;
- 30 (xi) the nucleotide sequence from positions 1-579 of SEQ ID No. 5;
- (xii) the nucleotide sequence from positions 665-1256 of SEQ ID No. 5;

- (xiii) a nucleotide sequence having at least 80%, preferably at least 90%, sequence identity to a sequences (i) - (xii);
- (xiv) an isolated fragment of (i) - (xiii); and
- (xv) a nucleotide sequence fully complementary to (i) - (xiv).

5 In the above, group (xiii) relates to variants of the polynucleotide depicted in groups (i) - (xii). The variant of the polynucleotide may be a naturally occurring allelic variant, from the same species or a different species, or a non-naturally occurring allelic variant. As known in the art an allelic variant is an alternate form of a polynucleotide sequence which may have a deletion, addition or substitution of one or more nucleotides.

10 Sequence identity can be assessed by best-fit computer alignment analysis using suitable software such as Blast, Blast2, FastA, Fasta3 and PILEUP. Preferred software for use in assessing the percent identity, i.e how two polynucleotide sequences line up is PILEUP. Identity refers to direct matches. In the context of the present invention, two polynucleotide sequences with 90% identity have 90% of the nucleotides being identical and in a like  
15 position when aligned optimally allowing for up to 10, preferably up to 5 gaps. The present invention particularly relates to polynucleotides which hybridise to one or other of the polynucleotide sequences (i) - (xv), under stringent conditions. As used herein, stringent conditions are those conditions which enable sequences that possess at least 80%, preferably at least 90%, more preferably at least 95% and more preferably at least 98% sequence identity  
20 to hybridise together. Thus, nucleic acids which can hybridise to one or other of the nucleic acids of (i) - (xv), include nucleic acids which have at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98% sequence identity and most preferably 100%, over at least a portion (at least 20, preferably 30 or more consecutive nucleotides) of the polynucleotide sequence of (i) - (xv) above.

25 As well as the novel intron sequences depicted in SEQ ID Nos. 1 - 5, smaller nucleic acid fragments thereof useful for example as oligonucleotide primers to amplify the flt-1 gene sequences or identify SNPs using any of the well known amplification systems such as the polymerase chain reaction (PCR), or fragments that can be used as diagnostic probes to identify corresponding nucleic acid sequences are also part of this invention. The invention  
30 thus includes polynucleotides of shorter length than the novel intron flt-1 sequences depicted in SEQ ID Nos.1 - 5 that are capable of specifically hybridising to the sequences depicted herein. Such polynucleotides may be at least 17 nucleotides in length, preferably at least 20,

more preferably at least 30 nucleotides in length and may be of any size up to and including or indeed, comprising the complete intron sequences depicted in SEQ ID Nos. 1 - 5.

An example of a suitable hybridisation solution when a nucleic acid is immobilised on a nylon membrane and the probe nucleic acid is greater than 300 bases or base pairs, say 500 bp, is: 6 x SSC (saline sodium citrate), 0.5% SDS (sodium dodecyl sulphate), 100µg/ml denatured, sonicated salmon sperm DNA. An example of a suitable hybridisation solution when a nucleic acid is immobilised on a nylon membrane and the probe is an oligonucleotide of between 12 and 50 bases is: 3M trimethylammonium chloride (TMACl), 0.01M sodium phosphate (pH 6.8), 1mM EDTA (pH 7.6), 0.5% SDS, 100µg/ml denatured, sonicated salmon sperm DNA and 0.1% dried skimmed milk. The hybridisation can be performed at 68°C for at least 1 hour and the filters then washed at 68°C in 1 x SSC, or for higher stringency, 0.1 x SSC/0.1% SDS. Hybridisation techniques are well advanced in the art. The person skilled in the art will be able to adapt the hybridisation conditions to ensure hybridisation of sequences with 80%, 90% or more identity.

15 A fragment can be any part of the full length sequence and may be single or double stranded or may comprise both single and double stranded regions. In a preferred embodiment, a fragment is a restriction enzyme fragment.

The nucleic acid sequences of the invention, particularly those relating to and identifying the single nucleotide polymorphisms identified herein represent a valuable information source with which to identify further sequences of similar identity and characterise individuals in terms of, for example, their identity, haplotype and other sub-groupings, such as susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard macromolecular structure programs or to search sequence databases using state of the art searching tools such as GCG (Genetics Computer Group), BlastX BlastP, BlastN, FASTA (refer to Altschul et al. J. Mol. Biol. **215**:403-410, 1990). Thus, the nucleic acid sequences of the invention are particularly useful as components in databases useful for sequence identity, genome mapping, pharmacogenetics and other search analyses. Generally, the sequence information relating to the nucleic acid sequences and polymorphisms of the invention may be reduced to, converted into or stored in 30 a tangible medium, such as a computer disk, preferably in a computer readable form. For

example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or more nucleic acid sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a nucleic acid comprising the sequence of a nucleic acid of the invention, a nucleic acid consisting of a nucleic acid of the invention, a nucleic acid which comprises part of a nucleic acid of the invention, which part includes at least one of the polymorphisms of the invention, a set of nucleic acid sequences wherein the set includes at least one nucleic acid sequence of the invention, a data set comprising or consisting of a nucleic acid sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein. The computer readable medium can be any composition of matter used to store information or data, including, for example, floppy disks, tapes, chips, compact disks, digital disks, video disks, punch cards and hard drives.

In another aspect of the invention there is provided a computer readable medium having stored thereon a nucleic acid sequence comprising at least 20 consecutive bases of the uPAR gene sequence, which sequence includes at least one of the polymorphisms at positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5).

In another aspect of the invention there is provided a computer readable medium having stored thereon a nucleic acid comprising any of the intron sequences disclosed in any of SEQ ID Nos. 1 - 5.

A computer based method is also provided for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising a polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism. Such a method is particularly useful in pharmacogenetic studies and in genome mapping studies.

In another aspect of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence



comprising at least 20 consecutive bases of the uPAR gene sequence, which sequence includes at least one of the polymorphisms at positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016), 454 (according to SEQ ID No. 3) and 696 5 (according to SEQ ID No. 5) in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid sequence to identify identity.

In another aspect of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing one or more of the following polymorphism containing nucleic acid sequences:

- 10 the nucleic acid disclosed in EMBL Accession Number X51602 with A at position 1953 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number X51602 with T at position 3453 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number X51602 with C at position 15 3888 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 519 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 786 according to the nucleotide positioning therein;
- 20 the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 1422 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in EMBL Accession Number D64016 with T at position 1429 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in SEQ ID No. 3 with G at position 454 according to the 25 nucleotide positioning therein;  
the nucleic acid sequence disclosed in SEQ ID No. 3 with A at position 454 according to the nucleotide positioning therein;  
the nucleic acid sequence disclosed in SEQ ID No. 5 with T at position 696 according to the nucleotide positioning therein;
- 30 the nucleic acid sequence disclosed in SEQ ID No. 5 with C at position 696 according to the nucleotide positioning therein;

or a complementary strand thereof or a fragment thereof of at least 17 bases comprising at least one of the polymorphisms, and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to determine identity.

The invention will now be illustrated but not limited by reference to the following  
5 Examples. All temperatures are in degrees Celsius.

In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

10 General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis  
15 (2.1.2).

## EXAMPLES

### Example 1 - Identification of Polymorphisms

#### **A. Methods**

20 In view of the large size of the flt-1 gene, scanning for SNPs was performed on sub-clones of the flt-1 gene. The sub-cloning strategy and primer positions used is disclosed below.

#### **DNA Preparation**

DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2<sup>nd</sup>  
25 Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

#### **30 Template Preparation**

Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature

94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR.

### Dye Primer Sequencing

Dye-primer sequencing using M13 forward and reverse primers was as described in the ABI protocol P/N 402114 for the ABI Prism™ dye primer cycle sequencing core kit with AmpliTaq FS™ DNA polymerase, modified in that the annealing temperature was 45° and DMSO was added to the cycle sequencing mix to a final concentration of 5 %.

The extension reactions for each base were pooled, ethanol/sodium acetate precipitated, washed and resuspended in formamide loading buffer.

4.25 % Acrylamide gels were run on an automated sequencer (ABI 377, Applied Biosystems).

## B. Results

### Primer design

#### 1. Primer locations for scan of Coding region and 3'UTR

All locations in this section refer to EMBL Accession X51602

EMBL Accession Number X51602 , 7680 bp

5' UTR (1-249), Coding (250-4266), 3'UTR (4267-7680)

#### 20 Exon boundaries within cDNA

Exon	Boundaries	Exon	Boundaries	Exon	Boundaries
Exon 1	1- 313	Exon 11	1686-1800	Exon 21	3046-3202
Exon 2	314-410	Exon 12	1801-1909	Exon 22	3203-3300
Exon 3	411-637	Exon 13	1919-2218	Exon 23	3301 -3423
Exon 4	638-762	Exon 14	2219-2365	Exon 24	3424 -3535
Exon 5	763-925	Exon 15	2366-2497	Exon 25	3536 -3635
Exon 6	926-1062	Exon 16	2498 -2604	Exon 26	3636 -3741
Exon 7	1063-1237	Exon 17	2605 -2737	Exon 27	3742 -3884
Exon 8	1238-1355	Exon 18	2738-2842	Exon 28	3885 -3969
Exon 9	1356-1525	Exon 19	2843- 2956	Exon 29	3970 -4064
Exon 10	1526-1685	Exon 20	2957- 3045	Exon 30	4065-7680

**Products requiring two stage amplification from c DNA****Primary product**

Product	Forward Primer	Reverse Primer	Temp	Time
1777-3946	1777-1804	3919-3946	55o	3 min

5

**Secondary Products (Primary product diluted 1000 x)**

Product	Forward Primer	Reverse Primer	Temp	Time
a. 1854-2435	1854-1877	2412-2435	58o	90 sec
b. 2288-2879	2288-2311	2857-2879	58o	90 sec
10 c. 2723-3310	2723-2746	3288-3310	58o	90 sec
d. 3157-3748	3157-3180	3725-3748	58o	90 sec

**Products amplified directly from cDNA**

Product	Forward Primer	Reverse Primer	Temp	Time
15 e. 293-696	292-313	673-696	55o	90 sec
f. 564-1133	564-587	1110-1133	55o	90 sec
g. 1031-1626	1031-1054	1603-1626	55o	90 sec
h. 1491-2046	1491-1514	2023-2046	55o	90 sec
i. 3662-4249	3662-3682	4226-4249	55o	90 sec

20

**Products amplified from genomic DNA**

Product	Forward Primer	Reverse Primer	Temp	Time
j. 4163-4744	4163-4182	4721-4744	55o	90 sec

**25 2. Primer locations for scan of promoter, 5' UTR, exon 1**

All locations in this section refer to EMBL Accession Number D64016

**EMBL Accession Number D64016, 1745 bp****Promoter region, exon 1, intron 1**

30

Product	Forward Primer	Reverse Primer	Temp	Time
k. 14-479	14-34	456-479	55o	90 sec

l. 343-890	343-366	869-890	550	90 sec
m. 762-1251	762-781	1232-1251	550	90 sec
n. 1151-1694	1151-1172	1673-1694	550	90 sec

- 5 For dye-primer sequencing these primers were modified to include the M13 forward and reverse primer sequences (ABI protocol P/N 402114, Applied Biosystems) at the 5' end of the forward and reverse oligonucleotides respectively.

### Novel Polymorphisms

- 10 Novel Polymorphisms within coding region - numbering refers to EMBL Accession Number X51602

(1)

Position	Polymorphism	Allele Frequency	No of Individuals
1953	G/A	G 90% A 10 %	31

15

- Polymorphism at position 1953 alters the third base of codon 568 (Threonine - ACG/ACA). It has been shown that single nucleotide polymorphisms can cause different structural folds of mRNA with potentially different biological functions (Shen et al 1999, *ibid*). The polymorphism can be detected by a diagnostic e RFLP since engineering of positions 1949,1950 creates a BsiWI recognition sequence (CGTACG). Polymorphism at position 1953 will modify the recognition sequence (CGTACG/A ).
- 20

### Diagnostic primer (positions 1919-1952 in X51602)

ATGGGTTTCATGTTA<sup>ACTTGGAAAAAATGCGTAC</sup>

- 25 modified residues in bold underline

### Reverse primer (positions 2098-2125 in X51602)

CATTCATGATGGTAAGATTAAGAGTGAT

- Amplification of genomic DNA with these primers will generate a PCR product of 206 bp. Digestion of a product from a wild type template with BsiWI (New England Biolabs) will give rise to products of 168bp and 38 bp. Digestion of a heterozygote product will generate products of 206 bp,168 bp and 38 bp. A product generated from a homozygote
- 30

variant will not be digested by BsiWI. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

(2)

5 Position	Polymorphism	Allele Frequency	No of Individuals
3453	C/T	C 70% T 30%	23

Polymorphism at position 3453 alters the third base of codon 1068 (Proline - CCC/CCT). It has been shown that single nucleotide polymorphisms can cause different structural folds of mRNA with potentially different biological functions (Shen et al 1999, *ibid*). The polymorphism at position 3453 can be detected by a diagnostic e RFLP, since modification of positions 3455, 3456, 3457 creates a PstI recognition sequence (CTGCAG). Polymorphism at position 3453 will modify the recognition sequence (CTGCATG).

- 15 **Diagnostic primer (Reverse, positions 3487-3454 in X51602, equivalent to positions 330-297 in Seq ID No 3)**

TCTTGGTTGCTGTAGATTTTGTCAAAGATAGCTGC

Modified residues in bold underline

**Forward primer (position 193-216 in Seq ID No 3)**

- 20 ACCCCATGGGACTCGGGTTGAAT

Amplification of genomic DNA with these primers will generate a PCR product of 137 bp. A product generated from a wild type template will not be digested by PstI (New England Biolabs). Digestion of a heterozygote product will give rise to products of 137 bp, 102 bp and 35 bp, digestion of a homozygous product will give rise to products of 102 bp and 35 bp. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

(3)

Position	Polymorphism	Allele Frequency	No of Individuals
3888	T/C	T 74 % C 26 %	23

5 Polymorphism at position 3888 alters the third base of codon 1213 (Tyrosine - TAT/TAC). It has been shown that single nucleotide polymorphisms can cause different structural folds of mRNA with potentially different biological functions (Shen et al 1999, *ibid*). Polymorphism at position 3888 creates a SnaI B recognition sequence (TACGTA).

#### 10 Forward primer (Positions 362-385 in Seq ID No 5)

CCTCAACCCTACAGAATGTGAATTG

#### Reverse primer (Positions 828-804 in Seq ID No 5)

CAGCTAGGTCTAGTTGTCAGTCCTC

15 Amplification of genomic DNA with these primers will generate a PCR product of 467 bp. A product generated from a wild type template will not be digested by SnaI B (New England Biolabs). Digestion of a heterozygote product will give rise to products of 467 bp, 245 bp and 222 bp, digestion of a homozygous variant product will generate products of 245 bp and 222 bp. Products can be separated and visualised on agarose gels following standard  
20 procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

Novel polymorphisms within promoter and 5' UTR -numbering refers to EMBL  
Accession Number D64016

25 (4)

Position	Polymorphism	Allele Frequency	No of Individuals
519	C/T	C 97% T 3 %	34

The polymorphism at position 519 can be detected by a diagnostic e RFLP, since  
30 modification of position 516 creates a potential SphI recognition sequence (GCATGC). Polymorphism at position 519 will modify the recognition sequence (GCACTGC).

Diagnostic primer (Positions 485-518 in D64016)

GGGTGCATCAATGCGGCCGAAAAAGACACGGGCA

Modified residues in bold underline

Constant primer (Positions 724-741 in D64016)

5 GTGTTCTTGGCACGGAGG

Amplification of genomic DNA with these primers will generate a PCR product of 256 bp. A product generated from a wild type template will not be digested by SphI (New England Biolabs). Digestion of a heterozygote product will generate products of 256 bp, 221 bp and 35 bp, digestion of a homozygote variant product will generate products of 221 bp and 35 bp. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

(5)

15 Position	Polymorphism	Allele Frequency	No of Individuals
786	C/T	C 98% T 2%	50

The polymorphism at position 786 can be detected by a diagnostic e RFLP. since modification of position 781,782 creates a NarI recognition sequence (GGCGCC).

20 Polymorphism at position 786 will modify the recognition sequence (GGCGCCC/T).

Diagnostic primer (Positions 751-785 in D64016)

GGCGCGGCCAGCTTCCCTTGGATCGGACTTGGCGC

Modified residues in bold underline

25 Constant primer (Positions 869-890 in D64016)

Amplification of genomic DNA with these products will generate a PCR product of 139 bp. Digestion of a product from a wild type template with NarI (New England Biolabs) will generate products of 105 bp and 34 bp. Digestion of a heterozygote product will generate products of 139 bp, 105 bp and 34 bp. The homozygous variant product will not be digested by NarI. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).



(6)

Position	Polymorphism	Allele Frequency	No of Individuals
1422	C/T	C 98% T 2%	25

5

Polymorphism at position 1422 alters an EagI recognition sequence (CGGCCTCG).

**Forward Primer (Positions 1251-1272 in D64016)**

**Reverse primer (Positions 1673-1694 in D64016)**

10

Amplification of genomic DNA with these primers generates a PCR product of 443 bp. Digestion of product from a wild type template with Eag I (New England Biolabs) will generate products of 271 bp and 143 bp. Digestion of a heterozygote product will generate products of 443 bp, 271 bp and 143 bp. The homozygous variant product will not be cleaved by Eag I. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

15

(7)

Position	Polymorphism	Allele Frequency	No of Individuals
20 1429	G/T	G 76% T 24%	25

The polymorphism at position 1429 can be detected by a diagnostic e RFLP, since modification of position 1431,1432 creates a Hinc II recognition sequence (GTTGAC). Polymorphism at position 1429 will modify the recognition sequence (G/TTTGAC).

25

**Diagnostic primer (Reverse, positions 1430-1463 in D64016)**

CTGCTCGCCCGGTGCCCCGCGCTCCCCGCGGTTAA

Modified bases in bold underline

**Constant primer (Forward, positions 1251-1272 in D64016)**

30

Amplification of genomic DNA with these primers will generate a PCR product of 212 bp. Digestion of product from a wild type template with Hinc II (New England Biolabs)

will generate products of 178 bp and 34 bp, digestion of a heterozygote product will give rise to products of 212 bp, 178 bp and 34 bp. A homozygote variant product will not be digested by Hinc II. Products can be separated and visualised on agarose gels following standard procedures (i.e. Molecular Cloning: Sambrook et al., 1989, *ibid*).

5

#### Novel polymorphism identified in intron 24

Primer locations for scan of intron 24, All locations in this section refer to Seq ID No 3.

10	Product	Forward Primer	Reverse Primer	Temp	Time
	193-538	193-216	538-515	55o	90 sec
	Position	Polymorphism	Allele Frequency	No of Individuals	
	454	G/A	G 76% A 24%	23	

#### 15 Novel polymorphism identified in intron 28

Primer locations for scan of intron 28, All locations in this section refer to Seq ID No 5.

	Product	Forward Primer	Reverse Primer	Temp	Time
	362-828	362-385	828-804	55o	90 sec
20	Position	Polymorphism	Allele Frequency	No of Individuals	
	696	T/C	T 76% C 24%	23	

#### Novel genomic sequence flanking exons within the human flt-1 gene

25 Two overlapping BAC clones were isolated - 51L6 (5') and 87P12 (3')

#### Sequencing Primers (positions refer to Accession X 51602)

##### Exon 17 (BAC clone 87P12)

30 Forward 2641-2664  
Reverse 2664-2641

**Exon 21 (BAC clone 87P12)**

Forward 1357-1380

Reverse 1380-1357

**5 Exon 24 (BAC clone 87P12)**

Forward 3452-3478

Reverse 3529-3506

**Exon 27 (BAC clone 87P12)**

10 Forward 3785-3811

Reverse 3811-3785

**Exon 28 (BAC Clone 87P12)**

Forward 3918-3946

15 Reverse 3946-3918

Application No: \_\_\_\_\_

Pillsbury Madison & Sutro

Inventor: J.C. SMITH

Filed: 2/8/01

Client & Ref. #: ASTRA ZENECA UK LTD (P) HM. 70675/US)

CL.# 9901 M# 277123